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The intracellular signaling mechanisms underlying the pathogenesis of cardiac diseases are not fully
understood. We report here that selective deletion of Shp2, an SH2-containing cytoplasmic tyrosine phos-
phatase, in striated muscle results in severe dilated cardiomyopathy in mice, leading to heart failure and
premature mortality. Development of cardiomyopathy in this mouse model is coupled with insulin resistance,
glucose intolerance, and impaired glucose uptake in striated muscle cells. Shp2 deficiency leads to upregula-
tion of leukemia inhibitory factor-stimulated phosphatidylinositol 3-kinase/Akt, Erk5, and Stat3 pathways in
cardiomyocytes. Insulin resistance and impaired glucose uptake in Shp2-deficient mice are at least in part due
to impaired protein kinase C-/ and AMP-kinase activities in striated muscle. Thus, we have generated a
mouse line modeling human patients suffering from cardiomyopathy and insulin resistance. This study
reinforces a concept that a compound disease with multiple cardiovascular and metabolic disturbances can be
caused by a defect in a single molecule such as Shp2, which modulates multiple signaling pathways initiated
by cytokines and hormones.
Heart failure is a serious life-threatening health problem
worldwide. Numerous studies have demonstrated a link be-
tween cardiac dysfunction and insulin resistance, as well as
deficiency in glucose transport (9, 35, 48). In the absence of
manifest diabetes, insulin resistance and minor degrees of glu-
cose intolerance are thought to be associated with and con-
tribute to the development of nonischemic cardiomyopathy or
idiopathic dilated cardiomyopathy (35, 45). However, the mo-
lecular basis for this link is poorly understood.
Muscle-specific gene knockout mice have presented unprec-
edented opportunities to decipher molecular signaling mech-
anisms underlying cardiomyopathic changes. Deletion of
PTEN in cardiomyocytes mediated by Mck-Cre results in car-
diac hypertrophy in mice (8). Dilated cardiomyopathy was also
observed to various degrees in mice with conditional ablation
of ErbB2 (HER2), 1 integrin, and the gp130 cytokine recep-
tor component in the heart or muscle (16, 34, 37). Interest-
ingly, despite the development of cardiomyopathy, most of
these mutant mice survive to adulthood with a normal life
span, suggesting limitations in their modeling of human pa-
tients’ pathological processes. These mutant mouse models
also show no correlation between cardiomyopathy and insulin
resistance. In fact, although muscle-specific PTEN knockout
mice develop cardiac hypertrophy (8), they are protected
against insulin resistance and diabetes induced by high-fat diet
due to enhanced insulin-stimulated glucose uptake in soleus
muscle (43).
Shp2 is a widely expressed cytoplasmic tyrosine phosphatase
with two SH2 domains that has been implicated in signaling
events downstream of receptors for growth factors, cytokines,
and hormones (25, 32). In particular, Shp2 has been shown to
participate in leptin and insulin signaling for the regulation of
energy balance and metabolism (23, 28, 46). In recent experi-
ments, several groups have identified germ line gain and loss-
of-function mutations in the human gene PTPN11, encoding
Shp2, in Noonan syndrome and LEOPARD (for lentigines,
electrocardiogram abnormalities, ocular hypertelorism, pul-
monic valvular stenosis, abnormalities of genitalia, retardation
of growth, and deafness) syndrome patients, respectively (21,
42). Paradoxically, these mutations either constitutively acti-
vate or inactivate the phosphatase activity leading to heart
diseases, among other disorders observed in Noonan or
LEOPARD syndrome patients. Since the conventional Shp2
knockout mice are embryonic lethal (36), tissue-specific dele-
tion of Shp2 will be required to determine a specific function
for Shp2 in the cardiovascular system in vivo.
We report here that striated muscle-specific Shp2 knockout
(MSKO) mice develop a severe dilated cardiomyopathy, re-
sulting in heart failure and premature death in mice. More
importantly, development of cardiomyopathy is associated with
insulin resistance, glucose intolerance, and impaired insulin-
stimulated glucose uptake in striated muscle cells in this mouse
model.
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Generation of MSKO mice. The Shp2 floxed allele and Mck-Cre mice have
been described previously (3, 46). Shp2flox/flox mice were used as controls,
Shp2flox/; Mck-Cre/ mice were used as a heterozygous mutant, and Shp2flox/flox;
Mck-Cre/ mice were used as homozygous mutant (MSKO). Mice were bred and
maintained according to the standard animal facility procedures. Deletion of
Shp2 exon4 was determined as previously described (46). Unless indicated, data
were collected from experiments on male animals.
Immunoblotting, immunoprecipitation, and kinase assay. Human insulin (5
U; Lilly) or mouse Leukemia Inhibitory Factor (LIF; 6  104 U/kg; Esgro) was
injected into the inferior vena cavas of 4- to 5-week-old mice. Whole-cell protein
extracts were isolated from the heart, muscle, and liver of each animal. Immu-
noprecipitation and immunoblot studies were performed according to standard
protocols. The rabbit polyclonal antibodies against phospho-Akt (Thr308 or
Ser473), Akt, phospho-AMP-kinase (phospho-AMPK), AMPK, phospho-Erk5,
Erk5 phospho-Erk1/2, Erk1/2, phospho-Jnk1/2, Jnk1/2, phospho-p90RSK,
p90rsk, phospho-p70s6k, p70s6k, phospho-protein kinase C (PKC)-/, and PKC-
/ were obtained from Cell Signaling. Rabbit polyclonal anti-Shp2 antibody was
generated in this laboratory, mouse -tubulin was obtained from Sigma, and
rabbit polyclonal GLUT4 was purchased at Chemicon. The Akt kinase assay was
performed as directed by Cell Signaling.
qRT-PCR. Total RNA was isolated by using the RNA STAT-60 reagent
protocol (Tel-Test). Quantitative reverse transcription-PCR (qRT-PCR) exper-
iments were carried out according to a one-step Sybr green qRT-PCR kit pro-
tocol (Stratagene) using an MX3000P thermal cycler (Stratagene). The primer
sequences used were 5-TTGGAGCAAATCCTGTGTAC-3 and 5-CTTCCTC
AGTCTGCTCACTC-3 for atrial natriuretic factor (ANF), 5-AAGAGTCCT
TCGGTCTCAAG-3 and 5-CCAGGAGGTCTTCCTACACC-3 for b-type na-
triuretic peptide (BNP), 5-TGCCAACAATGTCCTATCT-3 and 5-CTGCCT
CATCATACTCTTG-3 for skeletal -actin, 5-AACCTGGGAACAGAAAAC
TG-3 and 5-GGCAAAAGTAGGGAGACAAG-3 for phospholamban (PLN),
5-AGTCTTAACGGCAGTGTGAG3 and 5-GTTGCTAACAACGCACAT
G-3 for sarcoendoplasmic reticulum Ca2-ATPase (SERCA2a), and 5-GGTG
CTGACGGGAACAAC-3 and 5-CAGTTTTCAATGCTTTTGTTGG-3 for
MEF2C. Each reaction was done in triplicate, and the expression data were
normalized against GAPDH (glyceraldehyde-3-phosphate dehydrogenase).
Echocardiography analysis. Mice were anesthetized with isofluorane and sub-
jected to echocardiography as previously described (41).
Primary cardiomyocyte culture. For neonatal primary cardiomyocyte cultures,
1-day-old neonatal mice were used. Hearts were removed aseptically and main-
tained in Dulbecco modified Eagle medium–F-12 medium (DMEM/F12). The
cells were dissociated at 37°C by trypsin digestion 0.25% (wt/vol) (Sigma). The
digestion mixture was filtered by using a 70-m-pore-size nylon cell strainer (BD
Falcon) and centrifuged for 10 min at 1,000 rpm, and cells were resuspended in
DMEM/F12 with 20% fetal bovine serum. To exclude noncardiomyocytic cells,
the cell suspension was preplated at 37°C for 1 h on plastic dishes. The remaining
cells in the supernatant were then plated on collagen-coated dishes.
Electrophysiology. Electrophysiological patch clamp recordings were per-
formed using conventional whole-cell configuration from neonatal primary car-
diomyocytes, approximately 24 to 48 h after plating. ICa activation was measured
by 40-ms test pulses to a series of potentials (	40 mV to 60 mV at 10-mV
increments) applied at 10-s intervals from a holding potential of 	50 mV. The
capacitative currents evoked by the voltage jump were isolated with 2 mM
extracellular cobalt (Co2) and subtracted from the recorded calcium currents.
Total cell membrane capacitance was determined by integration of current tran-
sients in response to 10-mV test pulses. Calcium current density was used to
minimize the effects of cell size on calcium currents. Patch pipettes were pulled
to resistances of 2 to 3 M
. The data were analyzed on an IBM-compatible
computer interfaced to an Axopatch (200B) amplifier (Axon Instruments) under
the control of pCLAMP (version 8.0; Axon Instruments, Fremont, CA). The
voltage dependence of calcium current activation was determined by using an
interactive nonlinear regression-fitting procedure to the Boltzmann equation.
Graphics and statistical data analysis were performed by using Prism (GraphPad
Software, San Diego, CA).
Physiological assays. Blood glucose levels were assessed on whole venous
blood using a One Touch Basic (Lifescan) glucose monitor. Serum insulin levels
were measured by using the rat insulin enzyme-linked immunosorbent assay kit
(Crystal Chem). Glucose tolerance tests were performed on overnight (13 to
15 h)-fasted mice by intraperitoneal injection of D-glucose (2 g/kg [body weight];
Sigma). Insulin resistance was tested on randomly fed mice after intraperitoneal
injection of human insulin (1 U/kg [body weight]; Lilly). The serum-free fatty
acids were measured by using the NEFA C test kit (Wako). Serum triglycerides
were quantified using the triglyceride reagent set (Pointe Scientific, Inc).
Glucose uptake assays. Neonatal primary cardiomyocytes were used to mea-
sure glucose uptake, following published protocols (5, 11). Cells were plated in
DMEM/F12 at 105 cells/96 wells. After 48 h, the medium was removed, and cells
were washed with Krebs-Ringer phosphate-HEPES (KRPH) buffer and subse-
quently incubated with KRPH buffer at 37°C for 3 h. Insulin was added at various
concentrations in KRPH buffer for 30 min at 37°C. Cells were then incubated
with 0.2 Ci of 2-deoxy-D-[U-14C]glucose (Amersham Biosciences) plus 100 M
cold 2-deoxy-D-glucose (Sigma-Aldrich) for 3 h at 37°C. The cells were washed
with cold phosphate-buffered saline. For skeletal muscle, soleus muscles strips
were used to monitor glucose uptake according to a previously published pro-
tocol (44).
Statistical analysis. Statistical analyses were done by using the Student un-
paired t test. A P value of 0.05 was considered statistically significant. The data
are presented as means  the standard errors of the mean. Survival curves were
determined according to the Kaplan-Meier survival analysis.
RESULTS
Generation of MSKO Shp2 mice. In previous studies, we
generated a conditional Shp2 mutant allele (Shp2flox) in mice
using the Cre-loxP technology (46), which allows for cell-type-
specific Shp2 ablation. We generated a mouse strain with Shp2
selectively deleted in striated muscle by crossing Shp2flox/flox
mice with Mck-Cre transgenic animals that express the Cre
recombinase under the control of the muscle creatine kinase
promoter (Mck) (3). PCR analysis showed that Shp2 deletion
occurred selectively in cardiac and skeletal muscle, with no
DNA recombination events detected in other tissue/organs,
such as the liver, lung, spleen, and kidney (Fig. 1A). Shp2
protein was also dramatically reduced in cardiac and skeletal
muscles compared to controls (Fig. 1B), and the remaining
faint bands in muscle samples are likely due to Shp2 expression
in nonmyocytes such as fibroblast and endothelial cells. Shp2
ablation did not lead to increase in muscle expression levels of
Shp1, which is predominantly expressed in hematopoietic cells
(Fig. 1B). No obvious phenotypic differences were observed
between control (Shp2flox/flox) and heterozygous (Shp2flox/;
Mck-Cre/) mice, and thus most of the experiments were per-
formed by comparing control (Shp2flox/flox) and MSKO
(Shp2flox/flox; Mck-Cre/) male mice. Immunostaining of con-
trol cardiomyocytes revealed that Shp2 expression was primar-
ily localized to the T-tubular networks, while this expression
was not detected in MSKO cardiomyocytes (Fig. 1C).
MSKO mice exhibit early postnatal lethality and develop
dilated cardiomyopathy. Selective deletion of Shp2 in striated
muscle did not affect the Mendelian frequency of MSKO male
and female mice at birth. MSKO pups were viable up to 1 week
after birth, with no obvious phenotypic differences compared
to control littermates. However, MSKO mice began to die
within 2 weeks after birth (Fig. 1D). In contrast, the survival of
Shp2flox/fox control mice was 100%, as expected. The median
survival age for the mutant mice is 13.4 weeks, with very few
mice living up to 36 weeks. Between 5 and 9 weeks, no signif-
icant changes in body weights were observed between MSKO
and control mice (Fig. 1E). However, overall heart size was
significantly increased in MSKO mice compared to controls
(Fig. 1G). This was also reflected by the significant 66% in-
crease in heart/body weight ratios in MSKO mice relative to
controls (Fig. 1F).
Hematoxylin and eosin staining of MSKO hearts revealed
enlarged right and left ventricular chambers with thinner walls
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(Fig. 1H), which are common features of dilated cardiomyop-
athy. No significant abnormalities in liver, lung, and skeletal
muscle could be detected in MSKO mice (data not shown).
Masson’s trichrome staining of MSKO hearts performed at
different ages did not reveal evidence of fibrosis (data not
shown). In addition, no significant changes in apoptosis or
proliferation were detected in MSKO hearts compared to con-
trols (data not shown). Furthermore, no significant difference
in T-lymphocyte (CD4 and CD8) and macrophage (F4/80)
marker staining was detected between MSKO and control
hearts, suggesting a lack of lymphocyte and macrophage infil-
tration (data not shown).
To characterize cardiomyopathic changes in MSKO mice,
we examined expression profiles of genes typically associated
with cardiac stress (7, 17). mRNA levels of the ANF and BNP
genes were assessed in 4- to 5-week-old control and mutant
FIG. 1. MSKO mice exhibit dilated cardiomyopathy. (A) PCR detection of Mck-Cre-mediated recombination event in DNA extracts from
different tissues. Upper panel, Shp2flox allele; lower panel, Shp2null allele. M, molecular weight marker; Li, liver; L, lung; H, heart; M, skeletal
muscle; S, spleen; K, kidney. (B) Immunoblot analysis of Shp2 protein expression in tissues from Shp2flox/flox (control) and MSKO mice. Shp1
expression was examined in skeletal muscles derived from control and MSKO mice with -tubulin as a loading control (lower panels). (C) Im-
munofluorescence staining of cardiac left ventricular paraffin sections with antibodies to Shp2 (green) and anti-sarcomeric -actin (red), as well
as counterstained with DAPI (4,6-diamidino-2-phenylindole) (blue) (magnification, 60). (D) Kaplan-Meier survival curves for control and
MSKO mice (n  30). (E) Body weight comparison between 5- and 9-week-old control mice () and MSKO mice (f) (n  20). (F) Comparison
of heart weight/body weight ratios between 5- and 9-week-old control and MSKO mice (n  13). ***, P  0.001. (G) Gross morphology of a
representative heart from 12-week-old control and MSKO mice. (H) Transversal sections from 12 week-old control and MSKO mouse heart
stained with hematoxylin and eosin. The right ventricle (RV) and left ventricle (LV) are shown. All experiments were done on male mice.
FIG. 2. Analysis of cardiac gene expression profile and calcium currents in male MSKO mice. (A) qPCR was performed on total RNA extracted
from 4- to 5-week-old control () and MSKO (f) heart tissue. mRNA levels of ANF and BNP normalized against GAPDH are shown (n  3).
(B) Immunofluorescence staining of cardiac left ventricular sections with anti-ANF (green) and anti-sarcomeric -actin (red) and DAPI (blue)
(magnification, 60). (C) qPCR analysis of mRNA levels of PLN and SERCA2a (n  3). (D) L-type Ca2 channel currents (ICa) measurement
in postnatal primary cardiomyocyte derived from control (E) and MSKO (F) mice. Voltage-dependent changes in ICa in MSKO (n  13) and
control (n  14) cells. ICa was normalized to the cell capacitance to yield current densities (pA/pF). (E) Cell capacitance (pF) of control (n  14)
and MSKO (n  13) cardiomyocytes. *, P  0.05; **, P  0.01; ***, P  0.001.
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hearts. Notably, ANF and BNP expression was significantly
elevated in MSKO mice (Fig. 2A and B). In contrast,
SERCA2a expression was significantly downregulated in
MSKO hearts by 56%, while a modest decrease in PLN ex-
pression was also observed in MSKO mice compared to con-
trols (Fig. 2C). Both SERCA2a and PLN are known to be
downregulated in heart failure and are involved in Ca2 ho-
meostasis, which plays a pivotal role in myocyte contractility.
To detect alterations in L-type Ca2 channel activities, we
measured calcium currents (ICa) in cardiomyocytes by using
the whole-cell patch clamp technique. MSKO cardiomyocytes
exhibited significantly smaller ICa density (inward current am-
plitude normalized to cell capacitance, pA/pF) compared to
controls (Fig. 2D). The current-voltage relationship was simi-
lar between both groups, suggesting that the channel proper-
ties were not altered (Fig. 2D). Conversely, cardiomyocyte
capacitance, which is a measure of cell size, was significantly
augmented in MSKO cardiomyocytes (Fig. 2E). Specifically,
MSKO cells exhibited a twofold increase in capacitance com-
pared to controls (control, 23  4 pF, n  14; MSKO, 55  7
pF; n  13) (Fig. 2E), a finding consistent with the altered
expression profile of Ca2 homeostasis genes and cardiac dys-
function observed. The decrease in ICa density in MSKO car-
diomyocytes is likely a consequence of the increase in cell size
not being accompanied by an increase in the expression of
functional calcium channels.
Cardiac dysfunction in MSKO mice. The MSKO mice had
significant abnormalities in cardiac dimensions and function, a
finding suggestive of dilated cardiomyopathy. We then evalu-
ated heart performance by using echocardiographic analysis
(echo) in mutant and control male mice at an average age of 6
weeks (Table 1). Consistent with the histological analysis,
MSKO mice had an enlarged left ventricular chamber size as
evidenced by the significant increase in left ventricular internal
dimension values at end diastole and end systole. In addition,
significant wall thinning was seen in MSKO hearts, as evi-
denced by the significant decrease in systolic dimensions in
interventricular septal wall thickness. However, no significant
change in left ventricular posterior wall thickness was observed
between MSKO and control mice. These changes in cardiac
dimensions were accompanied by a striking decrease in cardiac
function in mutant mice, as evidenced by the significant de-
crease in left ventricular fraction shortening and the velocity of
circumferential fiber shortening. Echo analysis of left ventric-
ular mass further confirmed the increase in heart size in
MSKO mice.
Altered activation of PI3K/Akt pathway in hearts of MSKO
mice. Alteration of the phosphatidylinositol 3-kinase (PI3K)/
Akt pathway has been implicated in controlling cardiac size (4,
8, 27, 38). By direct immunoblot analysis, Akt phosphorylation
on Ser473 and Thr308 was significantly increased in MSKO
heart, compared to controls (Fig. 3A and C). Consistent with
this observation, we detected increased phosphorylation of
p70s6k, a downstream target of Akt in MSKO hearts. Phos-
phorylation of GSK-3/ on Ser21/9 residues, a substrate of
Akt, was also increased in MSKO hearts compared to controls
(Fig. 3B). However, no significant difference in Akt phosphor-
ylation was observed in skeletal muscle of MSKO and control
mice (Fig. 3C and D). These results suggest a unique negative
role for Shp2 in modulating the PI3K/Akt pathway in cardio-
myocytes.
Shp2 ablation leads to enhanced Erk5 and Stat3 activation
by LIF in cardiomyocytes. LIF is a member of the interleukin-6
family of cytokines, which has been implicated in heart failure
(18). We thus sought to examine the effects of LIF-induced cell
signaling in Shp2-deficient cardiomyocytes. After LIF stimula-
FIG. 3. Altered Akt activation status in the hearts of MSKO mice.
(A) p-Akt (Ser473 and Thr308) and p-p70s6k phosphorylation were
measured in 6- to 7-week-old heart lysates. (B) An Akt kinase assay
was performed with immunoprecipitated Akt on GSK3 as a substrate,
detected using anti-p-GSK3 / (Ser21/9). (C) Phosphoprotein levels
of p-Akt and p-p70s6k were quantitated relative to the control protein
amount (n  3). *, P  0.05. (D) p-Akt (Ser473) levels from 6- to
7-week-old skeletal muscle. All experiments were done on male ani-
mals.
TABLE 1. In vivo echocardiographic assessment of cardiac size and
function in control and MSKO (male) micea
Parameterb
Mean  SEMc
Control (n  7) MSKO (n  7)
BW (g) 24  0.8 25.4  0.7
IVSd (mm) 0.60  0.006 0.57  0.01*
IVSs (mm) 1.01  0.02 0.92  0.04*
LVIDd (mm) 3.63  0.08 4.54  0.25*
LVIDs (mm) 2.04  0.06 3.37  0.27**
LVPWd (mm) 0.63  0.01 0.59  0.01
LVPWs (mm) 1.18  0.03 1.09  0.05
HR (bpm) 463  35.4 454  33.8
LV FS (%) 43.9  1.4 26.4  2.2**
VCF (circ/s) 8.09  0.57 5.02  0.49*
Ao-ET (ms) 55.4  2.8 53.6  2.9
Ao-HR (bpm) 463.9  33.8 430.4  30.6
LVMd (mg) 70.8  3.4 97.6  8.2*
a Echocardiographic measurements were obtained from transthoracic
M-mode tracings of an average of 6-week-old mice.
b Abbreviations: BW, body weight; IVSd, interventricular septal wall thickness
at end diastole; IVSs, interventricular septal wall thickness at end systole;
LVIDd, left ventricular internal dimension at end diastole; LVIDs, left ventric-
ular internal dimension at end systole; LVPWd, left ventricular posterior wall
thickness at end diastole; LVPWs, left ventricular posterior wall thickness at end
systole; HR, heart rate; LV FS, left ventricular fractional shortening; VCF,
velocity of circumferential fiber shortening; Ao-ET, aortic ejection time; Ao-HR,
aortic heart rate; LVMd, left ventricular mass at end diastole.
c , P  0.05; , P  0.01.
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tion, Erk5 phosphorylation was upregulated in Shp2-deficient
hearts, while phospho-Erk1/2 levels were decreased (Fig. 4A).
To further confirm the enhanced Erk5 activation, we moni-
tored Mef2c expression and found that LIF-induced Mef2c
expression was increased in MSKO hearts compared to con-
trols (Fig. 4B). In addition, LIF-induced tyrosine phosphory-
lation of Stat3, which is associated with increased gp130 ty-
rosine phosphorylation, was elevated in MSKO hearts
compared to controls (Fig. 4A). This is consistent with our
previous observation of a negative role for Shp2 in modulation
of Stat3 activity (2, 46).
MSKO mice exhibit insulin resistance and glucose intoler-
ance. The effects of Shp2 deficiency on glucose homeostasis
and metabolism were assessed in MSKO mice. No significant
differences in blood glucose levels were observed in the fed and
fasted conditions between control and MSKO mice (Fig. 5A).
However, circulating insulin levels under the fed and fasted
conditions were slightly increased in sera of MSKO mice (Fig.
5B). As shown in Table 2, significantly elevated levels of tri-
glycerides were observed in the plasma, hearts, and muscles of
MSKO mice compared to controls. No increase in the amounts
of circulating free fatty acids was observed in MSKO mice, and
glycogen contents in cardiac and skeletal muscle in MSKO
mice were comparable to those of controls.
We performed an insulin tolerance test on 6- to 7-week-old
animals. Male and female MSKO mice displayed a remarkably
decreased ability to lower circulating blood glucose levels after
intraperitoneal injection of insulin (Fig. 5C). Consistent with
impaired insulin sensitivity, we observed glucose intolerance in
MSKO mice, with the most significant difference detected at
120 min after glucose injection (Fig. 5D). Therefore, MSKO
mice developed insulin resistance in association with dilated
cardiomyopathy.
Glucose uptake is impaired in Shp2-deficient cardiac and
skeletal muscle cells. To determine the cellular basis of insulin
resistance and glucose intolerance, we assessed the glucose
uptake capacity of Shp2-deficient cardiac and skeletal muscle
cells. Glucose transport was severely impaired in Shp2-defi-
cient cardiomyocytes, with a 50% decrease in 2-deoxyglucose
incorporation after 0.1 and 1 M insulin stimulation (Fig. 6A).
To determine glucose uptake in skeletal muscle, we isolated
soleus muscle and performed an ex vivo glucose transport
assay. As shown in Fig. 6B, glucose uptake was significantly
impaired in MSKO skeletal muscle compared to controls.
Therefore, Shp2 tyrosine phosphatase is required for insulin-
stimulated glucose uptake in both cardiac and skeletal muscle
cells.
To explore the molecular mechanism, we first examined
tyrosine phosphorylation (pY) levels of the insulin receptor
substrate-1 (IRS-1) protein. Surprisingly, insulin-induced pY-
IRS1 signals were enhanced in heart and muscle lysates from
MSKO mice compared to controls (Fig. 7A and B), with in-
creased amounts of the p85-IRS1 complex detected by coim-
munoprecipitation (Fig. 7A). Meanwhile, slightly lower levels
of IRS-1 phosphorylation on Ser612 was detected in MSKO
samples compared to controls (Fig. 7A and B). Notably, in-
creased pY-IRS-1 signals were not detected in liver lysates of
MSKO mice (Fig. 7C), in which Shp2 expression was not
changed. These results suggest that insulin resistance induced
by Shp2 deletion in muscle is not due to a defect at the level of
IRS1. It is more likely that Shp2 deletion caused changes in
other downstream signaling components, resulting in attenu-
ated insulin signaling. We then examined activities of Akt and
atypical PKC (PKC-/) after insulin stimulation. In MSKO
mice, PKC-/ activation was modestly decreased, with no dra-
matic change in Akt phosphorylation compared to controls
(Fig. 7D). Muscle glucose transport is also regulated by a
mechanism linked to the activation of AMPK. Metformin, a
biguanide drug, is known to reduce insulin resistance and in-
crease glucose uptake into peripheral tissues mainly by increas-
ing AMPK activity (14, 47). AMPK activation by metformin
FIG. 4. Changes in LIF-mediated signaling in cardiomyocytes. (A) LIF (6  104 U/kg) was injected into the cava veins of overnight-fasted mice,
and heart extracts were immunoblotted with antibodies as indicated. (B) qPCR analysis of MEF2C mRNA levels from 4- to 5-week-old hearts
(normalized against GAPDH), with or without LIF stimulation (10 min) (n  3). **, P  0.01.
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was remarkably decreased in MSKO heart and skeletal muscle
cells compared to controls (Fig. 7E).
Opposite effects of Shp2 on insulin-stimulated mitogen-ac-
tivated protein kinase pathways. Consistent with the bidirec-
tional effects of Shp2 in modulating Erk5 and Erk1/2 activation
by LIF in cardiomyocytes, we observed similar bidirectional
roles of Shp2 in the relay of insulin signaling. After insulin
stimulation, phospho-Erk1/2 and phospho-Jnk1/2 levels were
markedly decreased in Shp2-deficient cardiac and skeletal
muscle tissues (Fig. 7F). Consistently, insulin-induced activa-
tion of p90Rsk, a downstream target of Erk1/2, was downregu-
lated in MSKO cardiac and skeletal muscle compared to con-
trols (Fig. 7F). However, phospho-Erk5 signal was increased in
cardiac and skeletal muscles of mutant mice.
DISCUSSION
In this study, we show that mice with a conditional deletion
of Shp2 in muscle develop dilated cardiomyopathy and glucose
intolerance, and die prematurely in early postnatal life. The
development of dilated cardiomyopathy and heart failure in
MSKO mice is corroborated by the increased expression of
cardiac stress markers, such as ANF and BNP, in MSKO
hearts compared to controls. Downregulation of SERCA2a
was also observed in Shp2-deficient cardiomyocytes, and
SERCA2a is a critical factor in regulation of cardiac Ca2
homeostasis, with decreased expression detected during car-
diac dysfunction (29). Echocardiographic analysis of MSKO
hearts further demonstrated cardiac dysfunction coupled with
ventricular chamber dilatation, characteristic of dilated cardio-
myopathy. Molecular signaling analysis suggests that deletion
of Shp2 leads to altered LIF-induced intracellular signals, in-
cluding enhanced Stat3 and Erk5 activities, and impaired
FIG. 5. Metabolic characterization of MSKO mice. (A) Blood glucose measured on randomly fed (fed) or 16-h-fasted (fast) male (M) and
female (F) mice (n  20 to 25). (B) Serum insulin levels were measured in fed and fasted mice (n  7 to 10). (C) An insulin tolerance test was
performed on 6- to 7-week-old male mice and on 6- to 8-week-old female mice (n  7). (D) A glucose tolerance test was performed on 7- to
8-week-old 16-h-fasted male mice; n  7. Serum insulin was measured during the glucose tolerance test. *, P  0.05; **, P  0.01.




Control MSKO Control MSKO
Fasted FFA
(mmol/liter)
0.94  0.03 0.98  0.04 0.79  0.04 0.83  0.05
Fasted TG
(mmol/liter)
1.08  0.1 1.65  0.29* 0.56  0.03 1.0  0.17*
Fasted muscle
TG (mg/g)
1.79  0.67 2.65  0.89* 2.3  0.6 4.7  0.7*
Fasted heart
TG (mg/g)








4.5  0.2 3.6  0.2 4.9  0.2 4.2.  0.4
a Mice were examined at the age of 5 to 6 weeks.
b Abbreviations: FFA, free fatty acids; TG, triglycerides.
c n  7. , P  0.05.
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Erk1/2 activation. Consistently, Hagiwara et al. showed a pu-
tative role of Shp2 in mediating LIF-stimulated [Ca2]i tran-
sient and action potential duration increase in cardiomyocytes
using knockin mice lacking a Shp2 docking site on gp130, a
signal transducing component in LIF receptor (12). Heart-
specific overexpression of Stat3 induced myocardial hypertro-
phy in mice, with elevated expression of ANF, -myosin heavy
chain, and cardiotrophin-1 genes (24). Consistent with our
results, decreased Erk and Jnk activities were observed in a rat
model of heart failure and hypertension (19). Constitutive ac-
tivation of Mek5, the upstream kinase that activates Erk5,
induced cardiomyocyte elongation, leading to dilated cardio-
myopathy and sudden death in mice (33). The transcription
factor MEF2C has been shown to regulate postnatal heart
development and to control gene expression associated with
heart hypertrophy. Thus, the Erk5/MEF2C pathway is clearly
an important component in cardiac hypertrophy (1).
The development of dilated cardiomyopathy and impair-
ment of cardiac functions in MSKO mice are apparently due to
Shp2 deficiency intrinsic to cardiomyocytes, since a recent
study showed that mice with deletion of the Shp2 exon 11 in
cardiomyocytes mediated by -myosin heavy chain Cre exhib-
ited a phenotype similar to that induced by Mck-Cre (22). In
comparing our results to those of Kontaridis et al. (22), it is
interesting that mice with Mck-Cre-mediated exon 4 or exon
11 deletion of Ptpn11/Shp2 showed similar and consistent de-
fects in dilated cardiomyopathy, although with notable differ-
ences in severity. The most striking difference is that deletion
of exon 4 leads to early mortality in mice, whereas animals with
exon 11 ablation have normal life spans. Multiple factors can
contribute to this discrepancy, such as genetic background and
Cre-mediated DNA recombination efficiency, etc. In addition,
the consequence of exon 11 deletion is unclear, and it remains
to be clarified whether the removal of exon 11 creates a null
allele or a hypomorphic allele producing a C-terminal trun-
cated Shp2 protein.
Associations between cardiomyopathy, insulin resistance,
and alterations in glucose uptake have been previously re-
ported in human subjects (35). The molecular basis for this link
is unclear, which is largely due to the lack of proper animal
models for this complex disease. The most interesting pheno-
type of MSKO mice is the development of insulin resistance in
connection with the cardiac dysfunction phenotype. Both car-
diac and skeletal muscle cells in MSKO are defective in insu-
lin-induced glucose uptake. We believe that although Shp2
deficiency can play a direct causative role in dilated cardiomy-
opathy, the development of insulin resistance may aggravate
the progression of heart failure in MSKO mice. In examining
metabolic parameters, we found that MSKO mice displayed
hyperglyceridemia, an important symptom of metabolic syn-
dromes. This phenotype is very similar to that of muscle-spe-
cific insulin receptor knockout (MIRKO) mice, excluding the
appearance of dilated cardiomyopathy (3). MIRKO mice ex-
hibit hypertriglyceridemia and impaired glucose uptake in
muscle. Although MIRKO mice show a high level of insulin
resistance in isolated muscle, it seems insufficient to trigger
whole-body insulin resistance (3).
It is well known that Shp2 tyrosine phosphatase acts to
modulate the signal strength of multiple pathways, and there-
fore Shp2 ablation apparently disturbs numerous signaling cas-
cades. In previous experiments, we and others demonstrated
that Shp2 physically associates with IRS-1 in insulin-stimulated
cells (23). By docking on two phospho-tyrosyl residues
(pY1172 and pY1222) at the C-terminal tail (6, 40), Shp2 can
dephosphorylate the other phospho-tyrosine sites, such as
those for association with the p85 subunit of the PI3K (31).
Thus, mutating the two Shp2 docking sites leads to increased
tyrosine phosphorylation of IRS-1 and enhanced IRS-1/p85
binding (31). Consistently, we detected stronger pY-IRS-1 sig-
nals and increased IRS-1/p85 binding in Shp2-deficient muscle
cells. These biochemical data, which suggest a negative role of
Shp2 in modulating insulin signaling through IRS-1, are at
odds with the insulin resistance phenotype observed in MSKO
mice. The modest level of persistent hyperinsulinemia in
MSKO mice could contribute in part to development of insulin
resistance despite increased pY-IRS-1 signals. Furthermore,
disturbance of other downstream signaling pathways can offset
the effect of increased IRS-1 signaling and trigger insulin re-
sistance.
Insulin stimulates plasma translocation of glucose transport-
ers and consequently glucose uptake through multiple signal-
ing pathways, involving Akt and atypical PKC (PKC-/) (15,
39). Akt activation appears preserved in MSKO mice after
insulin stimulation, while phosphorylation of PKC-/ is de-
creased in striated muscles isolated from MSKO mice. A pre-
vious report has demonstrated that chronic heart failure pa-
tients also have impaired insulin-stimulated glucose uptake,
FIG. 6. Glucose uptake in cardiomyocytes and soleus muscle cells.
(A) 2-Deoxyglucose uptake in neonatal primary cardiomyocytes. The
uptake was determined at baseline and after 30 min of incubation with
0.1 or 1 M insulin. (B) Soleus muscles were isolated, and glucose
uptake was monitored ex vivo at baseline and after 30 min of incuba-
tion with 20 nM insulin (n  3 to 5). *, P  0.05; **, P  0.01.
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despite a normal level of Akt activity in skeletal muscle (20). A
mechanism partially dependent on ATP utilization leading to
an increased 5-AMP level and activation of AMPK has been
identified to regulate glucose transporter activity and muscle
glucose uptake (13, 30). We demonstrated here that AMPK
activation after metformin treatment was impaired in MSKO
mice. Therefore, selective deletion of Shp2 in striated muscle
affected both insulin- and non-insulin-dependent pathways re-
sponsible for glucose uptake. The positive effect of Shp2 in
mediating insulin-stimulated metabolic responses is consistent
with a previous study showing that transgenic expression of a
truncated protein containing the SH2 domains of Shp2 in-
duced insulin resistance in mice (26). This is in contrast to a
negative role of its close relative Shp1 in the modulation of
insulin signal strength (10).
Shp2 deficiency leads to decreased activation of Erk1/2 and
Jnk1/2 kinases by insulin but increased activity of Erk5 after
insulin stimulation. Thus, aberrant Erk1/2, Jnk1/2, and Erk5
activities apparently contribute to the metabolically defective
phenotype of MSKO mice. However, we wanted to reiterate
the point that deletion of Shp2 in striated muscle disturbed
multiple signaling pathways directly or indirectly, resulting in
the development of complex cardiac and metabolic disorders
in this mouse model. Heart failure has been identified as a
FIG. 7. Insulin-stimulated signaling events. (A to C) Insulin (5 U) was injected into the cava vein, and extracts of heart (A), muscle (B), or liver
(C) were subjected to immunoprecipitation or immunoblotting analysis with antibodies as indicated. (D) Tissue samples were collected as in panel
A, and immunoblot analyses were done with the indicated antibodies. (E) Metformin (0.4 g/kg) was injected in the cava vein for 5 min. Extracts
of heart and muscle were blotted with antibodies as indicated. (F) Insulin (5 U) was injected into the cava veins of overnight fasted mice. Heart
and muscle extracts were blotted with antibodies as indicated. The data shown are representative of at least three independent experiments.
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most common cause of mortality in diabetic patients, and in-
sulin resistance is also a major risk factor in cardiovascular
diseases. It is conceivable that the development and progres-
sion of a compound disease affecting several organs and tissues
could be caused by the accumulation of multiple defects, and
indeed experimental and clinical data suggest the involvement
of many genes in the etiology of metabolic disorders. Notably,
a defect in Ptpn11/Shp2 can also trigger a complex disease, as
the gene product acts to regulate multiple pathways. Thus, the
MSKO mouse will be a valuable model for the elucidation of
molecular links between cardiovascular and metabolic dis-
eases.
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